The NHS could be wasting millions of pounds by off-label use of an ineffective treatment for idiopathic pulmonary fibrosis when a licensed alternative exists, according to data presented at the British Thoracic Society meeting in London.
Study co-author Nazia Chaudhuri of the University Hospital of South Manchester, said that between 30% and 45% of patients with moderate IPF are currently treated using monotherapy with n-acetyl cysteine (NAC), despite recent data from the US PANTHER-IPF study showing lack of efficacy. The latter, conducted by the National Institutes of Health, found NAC to be no better than placebo for preserving lung function.
Help employers find you! Check out all the jobs and post your resume.
